Cargando…

Blood amyloid and tau biomarkers as predictors of cerebrospinal fluid profiles

INTRODUCTION: Blood biomarkers represent a major advance for improving the management, diagnosis, and monitoring of Alzheimer's disease (AD). However, their context of use in relation to routine cerebrospinal fluid (CSF) analysis for the quantification of amyloid peptides and tau proteins remai...

Descripción completa

Detalles Bibliográficos
Autores principales: Delaby, Constance, Alcolea, Daniel, Hirtz, Christophe, Vialaret, Jérôme, Kindermans, Jana, Morichon, Lisa, Fortea, Juan, Belbin, Olivia, Gabelle, Audrey, Blennow, Kaj, Zetterberg, Henrik, Lleó, Alberto, Lehmann, Sylvain
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Vienna 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8866346/
https://www.ncbi.nlm.nih.gov/pubmed/35169889
http://dx.doi.org/10.1007/s00702-022-02474-9
_version_ 1784655814826393600
author Delaby, Constance
Alcolea, Daniel
Hirtz, Christophe
Vialaret, Jérôme
Kindermans, Jana
Morichon, Lisa
Fortea, Juan
Belbin, Olivia
Gabelle, Audrey
Blennow, Kaj
Zetterberg, Henrik
Lleó, Alberto
Lehmann, Sylvain
author_facet Delaby, Constance
Alcolea, Daniel
Hirtz, Christophe
Vialaret, Jérôme
Kindermans, Jana
Morichon, Lisa
Fortea, Juan
Belbin, Olivia
Gabelle, Audrey
Blennow, Kaj
Zetterberg, Henrik
Lleó, Alberto
Lehmann, Sylvain
author_sort Delaby, Constance
collection PubMed
description INTRODUCTION: Blood biomarkers represent a major advance for improving the management, diagnosis, and monitoring of Alzheimer's disease (AD). However, their context of use in relation to routine cerebrospinal fluid (CSF) analysis for the quantification of amyloid peptides and tau proteins remains to be determined. METHODS: We studied in two independent cohorts, the performance of blood biomarkers in detecting “nonpathological” (A−/T−/N−), amyloid (A+) or neurodegenerative (T+ /N+) CSF profiles. RESULTS: Plasma Aβ(1–42)/Aβ(1–40) ratio and phosphorylated tau (p-tau(181)) were independent and complementary predictors of the different CSF profile and in particular of the nonpathological (A−/T−/N−) profile with a sensitivity and specificity close to 85%. These performances and the corresponding biomarker thresholds were significantly different from those related to AD detection. CONCLUSION: The use of blood biomarkers to identify patients who may benefit from secondary CSF testing represents an attractive stratification strategy in the clinical management of patients visiting memory clinics. This could reduce the need for lumbar puncture and foreshadow the use of blood testing on larger populations. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1007/s00702-022-02474-9.
format Online
Article
Text
id pubmed-8866346
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Springer Vienna
record_format MEDLINE/PubMed
spelling pubmed-88663462022-03-02 Blood amyloid and tau biomarkers as predictors of cerebrospinal fluid profiles Delaby, Constance Alcolea, Daniel Hirtz, Christophe Vialaret, Jérôme Kindermans, Jana Morichon, Lisa Fortea, Juan Belbin, Olivia Gabelle, Audrey Blennow, Kaj Zetterberg, Henrik Lleó, Alberto Lehmann, Sylvain J Neural Transm (Vienna) Neurology and Preclinical Neurological Studies - Original Article INTRODUCTION: Blood biomarkers represent a major advance for improving the management, diagnosis, and monitoring of Alzheimer's disease (AD). However, their context of use in relation to routine cerebrospinal fluid (CSF) analysis for the quantification of amyloid peptides and tau proteins remains to be determined. METHODS: We studied in two independent cohorts, the performance of blood biomarkers in detecting “nonpathological” (A−/T−/N−), amyloid (A+) or neurodegenerative (T+ /N+) CSF profiles. RESULTS: Plasma Aβ(1–42)/Aβ(1–40) ratio and phosphorylated tau (p-tau(181)) were independent and complementary predictors of the different CSF profile and in particular of the nonpathological (A−/T−/N−) profile with a sensitivity and specificity close to 85%. These performances and the corresponding biomarker thresholds were significantly different from those related to AD detection. CONCLUSION: The use of blood biomarkers to identify patients who may benefit from secondary CSF testing represents an attractive stratification strategy in the clinical management of patients visiting memory clinics. This could reduce the need for lumbar puncture and foreshadow the use of blood testing on larger populations. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1007/s00702-022-02474-9. Springer Vienna 2022-02-15 2022 /pmc/articles/PMC8866346/ /pubmed/35169889 http://dx.doi.org/10.1007/s00702-022-02474-9 Text en © The Author(s) 2022 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) .
spellingShingle Neurology and Preclinical Neurological Studies - Original Article
Delaby, Constance
Alcolea, Daniel
Hirtz, Christophe
Vialaret, Jérôme
Kindermans, Jana
Morichon, Lisa
Fortea, Juan
Belbin, Olivia
Gabelle, Audrey
Blennow, Kaj
Zetterberg, Henrik
Lleó, Alberto
Lehmann, Sylvain
Blood amyloid and tau biomarkers as predictors of cerebrospinal fluid profiles
title Blood amyloid and tau biomarkers as predictors of cerebrospinal fluid profiles
title_full Blood amyloid and tau biomarkers as predictors of cerebrospinal fluid profiles
title_fullStr Blood amyloid and tau biomarkers as predictors of cerebrospinal fluid profiles
title_full_unstemmed Blood amyloid and tau biomarkers as predictors of cerebrospinal fluid profiles
title_short Blood amyloid and tau biomarkers as predictors of cerebrospinal fluid profiles
title_sort blood amyloid and tau biomarkers as predictors of cerebrospinal fluid profiles
topic Neurology and Preclinical Neurological Studies - Original Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8866346/
https://www.ncbi.nlm.nih.gov/pubmed/35169889
http://dx.doi.org/10.1007/s00702-022-02474-9
work_keys_str_mv AT delabyconstance bloodamyloidandtaubiomarkersaspredictorsofcerebrospinalfluidprofiles
AT alcoleadaniel bloodamyloidandtaubiomarkersaspredictorsofcerebrospinalfluidprofiles
AT hirtzchristophe bloodamyloidandtaubiomarkersaspredictorsofcerebrospinalfluidprofiles
AT vialaretjerome bloodamyloidandtaubiomarkersaspredictorsofcerebrospinalfluidprofiles
AT kindermansjana bloodamyloidandtaubiomarkersaspredictorsofcerebrospinalfluidprofiles
AT morichonlisa bloodamyloidandtaubiomarkersaspredictorsofcerebrospinalfluidprofiles
AT forteajuan bloodamyloidandtaubiomarkersaspredictorsofcerebrospinalfluidprofiles
AT belbinolivia bloodamyloidandtaubiomarkersaspredictorsofcerebrospinalfluidprofiles
AT gabelleaudrey bloodamyloidandtaubiomarkersaspredictorsofcerebrospinalfluidprofiles
AT blennowkaj bloodamyloidandtaubiomarkersaspredictorsofcerebrospinalfluidprofiles
AT zetterberghenrik bloodamyloidandtaubiomarkersaspredictorsofcerebrospinalfluidprofiles
AT lleoalberto bloodamyloidandtaubiomarkersaspredictorsofcerebrospinalfluidprofiles
AT lehmannsylvain bloodamyloidandtaubiomarkersaspredictorsofcerebrospinalfluidprofiles